ASX:CSL

CSL Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume869,289 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend Yield0.99%
BetaN/A
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
CSL logo

Industry, Sector and Symbol

Stock Exchange ASX
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolASX:CSL
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.csl.com.au
Phone+61-3-93891911
EmployeesN/A
Year FoundedN/A

Debt

Debt-to-Equity Ratio75.13
Current Ratio3.05
Quick Ratio1.69

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E Growth2.43

Sales & Book Value

Annual Sales$9.98 billion
Price / Sales0.00
Cash FlowN/A
Price / Cash Flow207.70
Book ValueA$17.92 per share
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableOptionable

Headlines

Why the CSL (ASX:CSL) share price has rebounded 13% since March - The Motley Fool Australia
April 23, 2021 |  fool.com.au
Carlisle Companies Inc (CSL) Q1 2021 Earnings Call Transcript - Motley Fool
April 22, 2021 |  fool.com
Carlisle (CSL) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
April 22, 2021 |  finance.yahoo.com
Carlisle Cos. (CSL) Announces Plans for New Polyiso Insulation Manufacturing Facility in Sikeston, Missouri - StreetInsider.com
April 20, 2021 |  streetinsider.com
Haemonetics down 7% on agreement loss from CSL Pharma - Seeking Alpha
April 20, 2021 |  seekingalpha.com
Haemonetics (HAE) PT Lowered to $108 at Needham & Company; 'CSL Loss a Gut Punch But Not a Knock-Out' - StreetInsider.com
April 19, 2021 |  streetinsider.com
Haemonetics Slumps as CSL Plasma Declines to Renew a Supply Pact - TheStreet
April 19, 2021 |  thestreet.com
There Are Reasons To Feel Uneasy About Carlisle Companies' (NYSE:CSL) Returns On Capital - Nasdaq
April 13, 2021 |  nasdaq.com
CSL (ASX:CSL) share price falls amid ongoing AstraZeneca uncertainty
April 13, 2021 |  msn.com
CSL (ASX:CSL) share price falls amid ongoing AstraZeneca uncertainty - The Motley Fool Australia
April 13, 2021 |  fool.com.au
CSL Stock Is Believed To Be Fairly Valued - Yahoo Finance
April 13, 2021 |  finance.yahoo.com
Here's Why We Think CSL (ASX:CSL) Is Well Worth Watching - Yahoo Finance
April 11, 2021 |  finance.yahoo.com
Is the CSL (ASX:CSL) share price too cheap to ignore? - The Motley Fool Australia
April 11, 2021 |  fool.com.au
6 reasons CSL (ASX:CSL) shares are struggling - The Motley Fool Australia
April 8, 2021 |  fool.com.au
What’s happening with the CSL (ASX:CSL) share price? - The Motley Fool Australia
April 8, 2021 |  fool.com.au
CSL (ASX:CSL) share price wobbles on COVID vaccine news - The Motley Fool Australia
April 7, 2021 |  fool.com.au
CSL (ASX:CSL) share price remains near 52-week low on COVID-19 vaccine delays - The Motley Fool Australia
April 7, 2021 |  fool.com.au
Why the CSL (ASX:CSL) share price is going around in circles - The Motley Fool Australia
April 1, 2021 |  fool.com.au
Why the CSL (ASX:CSL) share price is going around in circles
April 1, 2021 |  msn.com
CSl is returning with original stars William Petersen and Jorja Fox
March 31, 2021 |  msn.com
See More Headlines

MarketRank™

Overall MarketRank™

0.77 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Receive CSL News and Ratings via Email

Sign-up to receive the latest news and ratings for CSL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CSL (ASX:CSL) Frequently Asked Questions

What stocks does MarketBeat like better than CSL?

Wall Street analysts have given CSL a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but CSL wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were CSL's earnings last quarter?

CSL Limited (ASX:CSL) issued its earnings results on Wednesday, August, 14th. The company reported $4.24 earnings per share for the quarter, topping the consensus estimate of $4.22 by $0.01.
View CSL's earnings history.

How often does CSL pay dividends? What is the dividend yield for CSL?

CSL declared a Interim dividend on Wednesday, February 24th. Investors of record on Wednesday, March 31st will be given a dividend of 1.3414 per share on Wednesday, March 31st. This represents a dividend yield of 0.5%. The ex-dividend date is Wednesday, March 3rd.
View CSL's dividend history.

Is CSL a good dividend stock?

CSL pays an annual dividend of A$2.70 per share and currently has a dividend yield of 0.99%. The dividend payout ratio of CSL is 35.66%. This payout ratio is at a healthy, sustainable level, below 75%.
View CSL's dividend history.

Who are CSL's key executives?

CSL's management team includes the following people:
  • Mr. Paul R. Perreault B.A., MD, CEO & Exec. Director (Age 64, Pay $4.23M)
  • Dr. Paul F. McKenzie, Chief Operating Officer (Age 55, Pay $2.74M)
  • Dr. Robert Andrew Cuthbertson A.O., BMedSci, MBBS, Ph.D., FTSE, FAHMS, AO, Sr. Adviser & Exec. Director (Age 66, Pay $1.48M)
  • Ms. Joy Carolyn Linton B.Com., BComm, Grad Dip AFI, GAICD, Chief Financial Officer (Age 56)
  • Mr. Mark Dehring, Head of Investor Relations
  • Mr. Gregory Boss B.S., BS(Hons), J.D., Exec. VP of Legal & Group Gen. Counsel (Age 60)
  • Christina Hickie, Sr. Mang. of Communications
  • Ms. Elizabeth Walker B.A., M.S., Exec. VP & Chief HR Officer (Age 51)
  • Dr. Karen Etchberger, Exec. VP of Quality & Bus. Services (Age 63)
  • Ms. Sharon McHale, Head of Public Affairs

Who are some of CSL's key competitors?

Some companies that are related to CSL include (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), 17031 (MYM), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), ADiTx Therapeutics (ADTX), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF) and Almirall (LBTSF).
View all of CSL's competitors.

What other stocks do shareholders of CSL own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CSL investors own include BHP Group (BHP), Commonwealth Bank of Australia (CBA), Cochlear (COH), ResMed (RMD), Telstra (TLS), Woodside Petroleum (WPL), Altium (ALU), Afterpay (APT), Appen (APX) and Berkshire Hathaway (BRK.B).

What is CSL's stock symbol?

CSL trades on the ASX under the ticker symbol "CSL."

How much money does CSL make?

CSL has a market capitalization of $0.00 and generates $9.98 billion in revenue each year.

How many employees does CSL have?

CSL employs 27,000 workers across the globe.

What is CSL's official website?

The official website for CSL is www.csl.com.au.

Where are CSL's headquarters?

CSL is headquartered at 45 Poplar Road,, Parkville, MELBOURNE, VIC 3052, Australia.

How can I contact CSL?

CSL's mailing address is 45 Poplar Road,, Parkville, MELBOURNE, VIC 3052, Australia. The company can be reached via phone at +61-3-93891911.


This page was last updated on 4/23/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.